• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Phosphate binders and management of hyperphosphataemia in end-stage renal disease.

作者信息

Savica Vincenzo, Calò Lorenzo A, Monardo Pietro, Santoro Domenico, Bellinghieri Guido

机构信息

Department of Nephrology, University of Messina and Nephrology Dialysis Unit 'Papardo' Hospital, Messina, Italy.

出版信息

Nephrol Dial Transplant. 2006 Aug;21(8):2065-8. doi: 10.1093/ndt/gfl289. Epub 2006 Jun 9.

DOI:10.1093/ndt/gfl289
PMID:16766546
Abstract
摘要

相似文献

1
Phosphate binders and management of hyperphosphataemia in end-stage renal disease.终末期肾病中磷酸盐结合剂与高磷血症的管理
Nephrol Dial Transplant. 2006 Aug;21(8):2065-8. doi: 10.1093/ndt/gfl289. Epub 2006 Jun 9.
2
[Clinical evidence and treatment for optimum concentration of parathyroid hormone, calcium and phosphate in chronic renal failure].[慢性肾衰竭中甲状旁腺激素、钙和磷最佳浓度的临床证据及治疗]
Clin Calcium. 2004 May;14(5):731-7.
3
Oral phosphate binders for the management of serum phosphate levels in dialysis patients.用于控制透析患者血清磷水平的口服磷结合剂。
J Ren Care. 2009 Mar;35 Suppl 1:65-70. doi: 10.1111/j.1755-6686.2009.00052.x.
4
The use of phosphate binders: data from contributors to the European Practice Database.
J Ren Care. 2009 Mar;35 Suppl 1:14-8. doi: 10.1111/j.1755-6686.2009.00051.x.
5
Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.慢性肾脏病中磷结合剂的益处与危害：随机对照试验的系统评价
Am J Kidney Dis. 2009 Oct;54(4):619-37. doi: 10.1053/j.ajkd.2009.06.004. Epub 2009 Aug 18.
6
[Effect of non-calcium-based phosphate binders on vascular calcifications in patients on hemodialysis: clinical experience and hypotheses].
G Ital Nefrol. 2011 Jul-Aug;28(4):357.
7
The crossover comparative trial of calcium acetate versus sevelamer hydrochloride (Renagel) as phosphate binders in dialysis patients.
Am J Kidney Dis. 2000 Jun;35(6):1248-50. doi: 10.1016/s0272-6386(00)70067-9.
8
Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients.钙盐在血液透析患者高磷血症治疗中的应用
Curr Opin Nephrol Hypertens. 2003 Jul;12(4):373-9. doi: 10.1097/00041552-200307000-00005.
9
The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.维持性透析患者中，柠檬酸铁磷酸盐结合剂与矿物质代谢及炎症标志物：一项随机临床试验预设分析的结果
Am J Kidney Dis. 2015 Sep;66(3):479-88. doi: 10.1053/j.ajkd.2015.03.013. Epub 2015 May 7.
10
Phosphate binders in CKD: chalking out the differences.慢性肾脏病中的磷酸盐结合剂：差异分析。
Pediatr Nephrol. 2010 Mar;25(3):385-94. doi: 10.1007/s00467-009-1329-0. Epub 2009 Nov 7.

引用本文的文献

1
Lanthanum Carbonate Opacities-A Systematic Review.碳酸镧混浊——一项系统评价
Diagnostics (Basel). 2022 Feb 11;12(2):464. doi: 10.3390/diagnostics12020464.
2
Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease.碳酸镧治疗终末期肾病患者高磷血症的安全性、有效性及耐受性的临床评估
Ther Clin Risk Manag. 2020 Sep 15;16:871-880. doi: 10.2147/TCRM.S196805. eCollection 2020.
3
Synthesis of Mg-Fe-Cl hydrotalcite-like nanoplatelets as an oral phosphate binder: evaluations of phosphorus intercalation activity and cellular cytotoxicity.
合成 Mg-Fe-Cl 水滑石纳米片作为口服磷结合剂：磷插层活性和细胞细胞毒性评价。
Sci Rep. 2016 Sep 1;6:32458. doi: 10.1038/srep32458.
4
Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide.用于治疗慢性肾脏病的磷结合剂：羟基氧化铁的作用
Int J Nephrol Renovasc Dis. 2016 Feb 2;9:11-9. doi: 10.2147/IJNRD.S78040. eCollection 2016.
5
Reduction of costs for anemia-management drugs associated with the use of ferric citrate.使用柠檬酸铁降低贫血管理药物的成本。
Int J Nephrol Renovasc Dis. 2014 May 20;7:191-201. doi: 10.2147/IJNRD.S65158. eCollection 2014.
6
Prescribing pattern of medicines in chronic kidney disease with emphasis on phosphate binders.慢性肾脏病药物处方模式，重点关注磷结合剂
Indian J Pharmacol. 2014 Jan-Feb;46(1):35-9. doi: 10.4103/0253-7613.125163.
7
Treatment options of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease stages 3 and 4: an historic review.3期和4期慢性肾病患者继发性甲状旁腺功能亢进（SHPT）的治疗选择：一项历史回顾
Clin Cases Miner Bone Metab. 2009 Sep;6(3):210-9.
8
Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients.含唾液磷酸结合剂的口香糖可降低透析患者的高磷血症。
J Am Soc Nephrol. 2009 Mar;20(3):639-44. doi: 10.1681/ASN.2008020130. Epub 2008 Nov 19.